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Epilepsy is a very serious neurological disorder which
is often underrepresented. Around 50 million indi-
viduals worldwide have active epilepsy with recurrent
seizures and in spite of the medical advances over the
years, 30% of these patients remain as drug resistant
(Pati and Alexopoulos, 2010). Even after several years
of research, there is still a lack of good understanding
on the pathophysiology of seizure disorders (Perucca,
2011). Investigators in this field believe that there is
a great need for novel antiepileptic drugs (AEDs) that
act differently than the drugs available on the market.
The majority of AEDs act by blocking sodium chan-
nels (phenytoin, carbamazepine) or by the augment of
GABAergic transmission (phenobarbital, valproic acid).
A newer generation of AEDs has expanded therapeutic
options, however these are not superior to the older
drugs (Hitiris and Brodie, 2006). Patients with mesial
temporal lobe epilepsy (mTLE) are among the most
pharmacoresistant to these medications (Pati and Alex-
opoulos, 2010). In order to attempt the rectification
of this dilemma, the neuropharmacologist needs to not
only try and find AEDs with new mechanisms of action,
but to also keep in mind what information is currently
available on the pathophysiology of epilepsy. It is clear
that during the complicated process of epileptogenesis,
several different mechanisms are taking place, thus one
should ideally identify new compounds that are capable
of targeting different pathways simultaneously. The
focus of epilepsy researchers is to identify compounds
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that are not only capable of attenuating seizures (anti-
convulsant), but are also antiepileptogenic (can prevent
epilepsy) or disease-modifying (halting its progression).
A lot of interest is being shown towards neuropeptides
as a way to suppress epileptic seizures. A number of
neuropeptides have been extensively studied in the
pathogenesis of epilepsy, such as neuropeptide Y,
galanin and somatostatin. However the poor ability of
these neuropeptides to penetrate the blood brain barrier
(BBB) serves as the main obstacle for brain drug devel-
opment (Robertson et al., 2011). Neuropeptide-based
treatments present a number of advantages in compari-
son to treatments that target classical neurotransmitter
systems and ion channels, both in efficacy as well as
safety (Hokfelt et al., 2003; Portelli et al., 2012a). Since
neuropeptides are normally released from neurons in
the presence of high frequency firing or pathological
conditions, a likely advantage is that the clinical effects
of neuropeptide receptor antagonists will only become
evident under epileptic conditions where high frequency
firing is involved, which in turn reduces the risk of
adverse effects. Ghrelin, a pleiotropic peptide that
has excited the scientific community generally since its
discovery in 1999, has recently been introduced in the
field of epilepsy.
Ghrelin is produced both centrally and peripher-
ally. Ghrelin requires modification on the serine-3 by
O-acylation with octanoate in order to bind to the
G-protein coupled receptor (GPCR) growth hormone
secretagogue receptor type 1a (GHSR1a) (Kojima et al.,
1999). The ghrelin receptor gene encodes two types
of GHSR mRNA, known as 1a and 1b, resulting in
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Figure 1: Some of the known effects of ghrelin, which makes this neuropeptide system a promising target for antiepileptic and
antiepileptogenic treatments.
two isoforms: GHSR1a and GHSR1b (Camina, 2006).
GHSR1a is given more importance, since GHSR1b is
unable to bind or be activated by ghrelin. GHSR1a,
as with ghrelin, is widely expressed both centrally and
peripherally, including in seizure-prone regions such as
the hippocampus. For a more detailed account of the
cell biology of the ghrelin receptor, please refer to the
review by Camina (2006).
In the past six years the ghrelin system has been
reported to have anticonvulsant properties. Ghrelin
has been shown to have an inhibitory effect on seizures
induced by pentylenetetrazole (Obay et al., 2007; Obay
et al., 2008), penicillin (Aslan et al., 2009), and kainic
acid (Lee et al., 2010), but its anticonvulsant mechanism
of action has remained elusive. Recently we have at-
tempted to unravel ghrelin’s anticonvulsant mechanism
of action using the in vivo rat model for pilocarpine-
induced limbic seizures, the mouse pilocarpine tail
infusion model, transgenic mice with a GHSR deletion,
electrophysiology in hippocampal slices, EEG recording
in freely moving rats, and HEK293 cells expressing the
human GHSR, to determine inverse agonism, activa-
tion, desensitization, internalization and resensitization
(Portelli et al., 2012b). Ghrelin and the ghrelin-mimetic
capromorelin attenuated pilocarpine-induced seizures
in rats and mice. Experiments with transgenic mice
established that ghrelin requires the GHSR for its
anticonvulsant effect. Interestingly we found that
GHSR−/− mice had a higher seizure threshold than
GHSR+/+ mice when administered the muscarinic
agonist pilocarpine. This prompted us to look further
into pharmacological modulation of the receptor, where
we discovered that abolishing the constitutive activity
of GHSR by inverse agonism results in the attenuation
of seizures and epileptiform activity. We verified that
ghrelin’s potential to rapidly desensitize the GHSR is
followed by internalization of the receptor and a slower
resensitization process. This, together with our present
novel findings that different ghrelin fragments possess
similar agonistic potencies but different desensitization
characteristics on the GHSR, led us to elucidate that
ghrelin probably attenuated limbic seizures in rodents
and epileptiform activity in hippocampal slices due to
the desensitizing effect on the GHSR (Portelli et al.,
2012b). This in turn constitutes a novel mechanism of
anticonvulsant action whereby an endogenous agonist
reduces the activity of a constitutively active receptor.
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Ghrelin presents a number of advantages when
compared to other well-established anticonvulsant
neuropeptides. This neuropeptide can easily cross the
BBB, and the ghrelin system has been attributed to
affect a number of physiological processes, ranging
from its potent anti-inflammatory and neuroprotective
properties to its ability to protect the BBB and induce
hippocampal neurogenesis (Moon et al., 2009; Portelli
et al., 2012a) (Fig 1). Studies have shown that during
the process of epileptogenesis, all previously mentioned
physiological processes are negatively affected (Ravizza
et al., 2006; Boer et al., 2008; Choi and Koh, 2008;
Ravizza et al., 2008; Vezzani et al., 2011; Zlokovic,
2008; Coremans et al., 2010; Marchi et al., 2012; Parent
and Kron, 2012; Vezzani et al., 2013). Recently, a
clinical phase III trial for the ghrelin receptor agonist
JMV1843 (Macimorelin), indicated for growth hormone
deficiency in humans, has been completed and the drug
was found to be well tolerated. It is now currently
being developed by the company Æterna-Zentaris.
Our knowledge on the role of the ghrelin axis in the
pathogenesis of epilepsy is still in its infancy. Targeting
the ghrelin receptor has been shown to attenuate acute
seizures in different models (Obay et al., 2007; Obay
et al., 2008; Xu et al., 2009; Lee et al., 2010; Portelli
et al., 2012a; Portelli et al., 2012b), and from what is
already known with regard to this system’s properties
in view of inflammatory cascades, neuroprotection, neu-
rogenesis, and BBB protection, it is promising that the
ghrelin axis could play a role in the process of epilepto-
genesis.
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